Walker, M., Specht, S., Churcher, T. S., Hoerauf, A., Taylor, Mark ORCID: https://orcid.org/0000-0003-3396-9275 and Basanez, M.-G. (2014) 'Therapeutic Efficacy and Macrofilaricidal Activity of Doxycycline for the Treatment of River Blindness'. Clinical Infectious Diseases, Vol 60, Issue 8, pp. 1199-1207.
Full text not available from this repository.Abstract
Background.
Onchocerca volvulus and lymphatic filariae, causing river blindness and elephantiasis, depend on endosymbiotic Wolbachia bacteria for growth, development, fertility, and survival. Clinical trials have shown that doxycycline treatment eliminates Wolbachia, causing long-term sterilization of adult female filariae and effecting potent macrofilaricidal activity. The continual reinfection by drug-naive worms that occurs in these trial settings dilutes observable anti-Wolbachia and antifilarial effects, making it difficult to estimate therapeutic efficacy and compare different doxycycline regimens, evaluated at different times after treatment.
Methods.
A meta-analytical modeling framework is developed to link all usable data collected from clinical trials measuring the Wolbachia status and viability of individual female adult worms collected at various times after treatment with 4, 5, or 6 weeks of daily 100 or 200 mg oral doxycycline. The framework is used to estimate efficacy parameters that are not directly measurable as trial outcomes.
Results.
The estimated efficacy of doxycycline (the maximum proportional reduction in the percentage of adult female O. volvulus positive for Wolbachia) is 91%–94% on average, irrespective of the treatment regimen. Efficacy is >95% in the majority of trial participants. The life span of Wolbachia-depleted worms is reduced by 70%–80%, from approximately 10 years to 2–3 years.
Conclusions.
The efficacy parameters are pertinent to the prospects of using doxycycline on a “test and treat” basis for onchocerciasis control and confirm doxycycline as a potent macrofilaricidal therapy. The modeling approach is more generally relevant to the design and evaluation of clinical trials for antifilarial drugs conducted in endemic settings.
Item Type: | Article |
---|---|
Subjects: | QV Pharmacology > QV 38 Drug action. QV Pharmacology > Drug Standardization. Pharmacognosy. Medicinal Plants > QV 771 Standardization and evaluation of drugs QX Parasitology > Helminths. Annelida > QX 301 Filarioidea WC Communicable Diseases > Tropical and Parasitic Diseases > WC 880 Filariasis and related conditions (General) WC Communicable Diseases > Tropical and Parasitic Diseases > WC 885 Onchocerciasis |
Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
Digital Object Identifer (DOI): | https://doi.org/10.1093/cid/ciu1152 |
Depositing User: | Martin Chapman |
Date Deposited: | 18 Feb 2015 15:03 |
Last Modified: | 16 Sep 2019 09:01 |
URI: | https://archive.lstmed.ac.uk/id/eprint/4861 |
Statistics
Actions (login required)
Edit Item |